Relapsing Multiple Sclerosis Study – Now Enrolling
The main purpose of this study is to find out if patients treated with ofatumumab may experience fewer MS relapses than patients treated with Aubagio® (also known as teriflunomide). Teriflunomide is an approved medication for the treatment of relapsing MS.
MS is a long-term illness where the body’s immune system attacks and damages the protective covering (called myelin) around the nerves in the central nervous system. Damaged myelin results in scar tissue or “sclerosis”. Because this scar tissue does not transfer signals from the brain as well as normal myelin, nerves stop working properly. Such scars can be seen on a scan called magnetic resonance imaging (MRI). People with relapsing MS (relapsing-remitting MS or secondary progressive MS with relapses) will have repeated attacks, or “relapses”. During these relapses, the immune system attacks the nerves in the brain or spinal cord, damaging the myelin covering. This can result in symptoms including difficulty walking, balance problems, vision problems, and more. Some symptoms may not completely recover after the relapse leading to accumulation of disability over time.
During the study treatment period, patients receive either ofatumumab or teriflunomide. The assignment of patients to treatment groups will be done equally using ‘randomization’ so that half of the patients will be assigned to the ofatumumab group and half to the teriflunomide group. For this study there are 3 visits one week apart in the first month followed by the Month 1 and Month 3 visits. After that, the study visits occur at 3-monthly intervals.
If you, your family member or loved one is interested in learning more about participating in this study, please contact the Study Coordinator at 520-320-2157.